Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Jing Xue

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-6497-1792; OpenAlex author ID A5047995132. Sources: OpenAlex.

Their work

Papers
24 (first author 2, last author 10)
Trials
0
Grants
0
Labs led
1
Collaborators
95
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 3 papers · 2020: 1 paper · 2021: 3 papers · 2022: 3 papers · 2023: 2 papers · 2024: 5 papers · 2025: 1 paper · 2026: 3 papers

Papers 24

  1. A peritumoral microenvironment engaged by Reg-EXTL3 axis fosters nerve-cancer interactions in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.neuron.2026.03.039↗
  2. Epigenetic dysregulation and microenvironment remodeling in pancreatic cancer. Last author DOI 10.1016/j.trecan.2026.01.011↗
  3. A STING signaling relay from tumor cells to macrophages mediates the improved efficacy of combination chemotherapy in pancreatic cancer. Co-author DOI 10.1186/s12929-026-01226-1↗
  4. Targeting pancreatic cancer glutamine dependency confers vulnerability to GPX4-dependent ferroptosis. Last author DOI 10.1016/j.xcrm.2025.101928↗
  5. SIN3B Loss Heats up Cold Tumor Microenvironment to Boost Immunotherapy in Pancreatic Cancer. Last author DOI 10.1002/advs.202402244↗
  6. Deciphering fatty acid biosynthesis-driven molecular subtypes in pancreatic ductal adenocarcinoma with prognostic insights. Co-author DOI 10.1007/s13402-024-00953-7↗
  7. Tumor cell-intrinsic epigenetic dysregulation shapes cancer-associated fibroblasts heterogeneity to metabolically support pancreatic cancer. Last author DOI 10.1016/j.ccell.2024.03.005↗
  8. Deciphering the pancreatic cancer microbiome in Mainland China: Impact of Exiguobacterium/Bacillus ratio on tumor progression and prognostic significance. Co-author DOI 10.1016/j.phrs.2024.107197↗
  9. MED12 loss activates endogenous retroelements to sensitise immunotherapy in pancreatic cancer. Last author DOI 10.1136/gutjnl-2024-332350↗
  10. Clostridium butyricum and its metabolite butyrate promote ferroptosis susceptibility in pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s13402-023-00831-8↗
  11. Oncogenic KRAS triggers metabolic reprogramming in pancreatic ductal adenocarcinoma. Last author DOI 10.2478/jtim-2022-0022↗
  12. Smad4 Deficiency Promotes Pancreatic Cancer Immunogenicity by Activating the Cancer-Autonomous DNA-Sensing Signaling Axis. Co-author DOI 10.1002/advs.202103029↗
  13. Glycolysis addiction compensating for a defective pentose phosphate pathway confers gemcitabine sensitivity in SETD2-deficient pancreatic cancer. Co-author DOI 10.1016/j.bbrc.2022.05.047↗
  14. SULF2 enhances GDF15-SMAD axis to facilitate the initiation and progression of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.215693↗
  15. Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor prognosis but better immunotherapy response. Co-author DOI 10.1038/s41421-021-00271-4↗
  16. Mutant Kras co-opts a proto-oncogenic enhancer network in inflammation-induced metaplastic progenitor cells to initiate pancreatic cancer. Co-author DOI 10.1038/s43018-020-00134-z↗
  17. Integrated genomic and transcriptomic analysis reveals unique characteristics of hepatic metastases and pro-metastatic role of complement C1q in pancreatic duc… Co-author DOI 10.1186/s13059-020-02222-w↗
  18. Perineural Invasion Reprograms the Immune Microenvironment through Cholinergic Signaling in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-19-2689↗
  19. CD90 highly expressed population harbors a stemness signature and creates an immunosuppressive niche in pancreatic cancer. Last author DOI 10.1016/j.canlet.2019.03.051↗
  20. THZ1 reveals CDK7-dependent transcriptional addictions in pancreatic cancer. Last author DOI 10.1038/s41388-019-0701-1↗
  21. Inflammation and development of pancreatic ductal adenocarcinoma. First author DOI 10.21037/cco.2019.04.02↗
  22. IL22RA1/STAT3 Signaling Promotes Stemness and Tumorigenicity in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-17-3131↗
  23. HDAC3 mediates smoking-induced pancreatic cancer. Co-author DOI 10.18632/oncotarget.6820↗
  24. Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma. First author DOI 10.1053/j.gastro.2012.12.042↗

Closest collaborators

The 25 strongest of 95 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ningning Niu · 12 shared papers, 2019–2026 · strength 2.24
  2. Yongwei Sun · 11 shared papers, 2018–2024 · strength 1.35
  3. Xuqing Shen · 6 shared papers, 2022–2025 · strength 1.17
  4. Ping Lu · 8 shared papers, 2018–2025 · strength 0.99
  5. Junyi Xu · 4 shared papers, 2023–2024 · strength 0.89
  6. Zhengyan Zhang · 4 shared papers, 2023–2024 · strength 0.82
  7. Yingying Tang · 4 shared papers, 2024–2025 · strength 0.77
  8. Minwei Yang · 6 shared papers, 2018–2024 · strength 0.65
  9. Liwei Wang · 4 shared papers, 2019–2025 · strength 0.50
  10. Juanjuan Shi · 4 shared papers, 2018–2022 · strength 0.48
  11. Yan‐Miao Huo · 4 shared papers, 2018–2022 · strength 0.38
  12. Massimiliano Mazzone · 2 shared papers, 2024 · strength 0.38
  13. Xiaojun Xia · 2 shared papers, 2022–2026 · strength 0.36
  14. Zhigang Zhang · 4 shared papers, 2018–2021 · strength 0.34
  15. Hong‐Fei Yao · 2 shared papers, 2022–2026 · strength 0.34
  16. Tiebo Mao · 2 shared papers, 2021–2025 · strength 0.32
  17. Juanjuan Shi · 3 shared papers, 2019–2022 · strength 0.32
  18. Jian‐Yu Yang · 3 shared papers, 2020–2022 · strength 0.31
  19. Xueliang Fu · 3 shared papers, 2020–2022 · strength 0.31
  20. Dejun Liu · 3 shared papers, 2020–2022 · strength 0.31
  21. Ping Lü · 1 shared paper, 2024 · strength 0.31
  22. Ruizhe He · 3 shared papers, 2019–2022 · strength 0.30
  23. Li-Peng Hu · 2 shared papers, 2020–2026 · strength 0.28
  24. Shu‐Heng Jiang · 2 shared papers, 2020–2026 · strength 0.28
  25. Yuan Fang · 3 shared papers, 2018–2019 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.